Effect of 12 Months Supplementation With a Symbiotic Lozenge on Caries Increment in Healthy Children (PiP-C)
Primary Purpose
Dental Caries
Status
Completed
Phase
Not Applicable
Locations
Denmark
Study Type
Interventional
Intervention
2 billion CFU in total of the two strains Lactobacillus paracasei subsp. paracasei and Lactobacillus rhamnosus and arginine.
Placebo
Sponsored by
About this trial
This is an interventional prevention trial for Dental Caries
Eligibility Criteria
Inclusion Criteria:
- Healthy children with absence of severe chronic disease
- Age 5-8 years, both inclusive, at inclusion
- Ability to cooperate at dental examination
- Ability to cooperate to a daily intake of a lozenge
- Parents/legal guarding provided voluntary written informed consent
Exclusion Criteria:
- Children with severe medical conditions
- Mentally or physically disabled children
- Children of parents with language barriers and not able to give written informed consent
Sites / Locations
- University of Copenhagen
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Placebo Comparator
Arm Label
Active
Placebo
Arm Description
A lozenge containing 2 billion CFU in total of the two strains Lactobacillus paracasei subsp. paracasei and Lactobacillus rhamnosus and arginine 2% to be taken once daily
An identical lozenge except for the absence of probiotics and arginine to be taken once daily.
Outcomes
Primary Outcome Measures
Increase in caries incidence
Caries increment in primary molar teeth, primary canines and erupted occlusal surfaces at the first permanent molar teeth in children aged 5-8 years, using a modified dmf-s scale, including the occlusal surfaces of the first permanent teeth where d is defined by ICDAS scale and assessed both clinically and by dental x-ray.
Secondary Outcome Measures
Full Information
NCT ID
NCT03928587
First Posted
April 17, 2019
Last Updated
September 30, 2022
Sponsor
Chr Hansen
Collaborators
University of Copenhagen
1. Study Identification
Unique Protocol Identification Number
NCT03928587
Brief Title
Effect of 12 Months Supplementation With a Symbiotic Lozenge on Caries Increment in Healthy Children
Acronym
PiP-C
Official Title
Effect of 12 Months Supplementation With a Symbiotic Lozenge on Caries Increment in Healthy Children: A Randomized, Parallel-grouped, Placebo-controlled Trial
Study Type
Interventional
2. Study Status
Record Verification Date
September 2022
Overall Recruitment Status
Completed
Study Start Date
May 1, 2019 (Actual)
Primary Completion Date
October 8, 2021 (Actual)
Study Completion Date
October 8, 2021 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Chr Hansen
Collaborators
University of Copenhagen
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
The primary objective of this trial is to investigate the effect of a symbiotic lozenge on dental caries in young children.
Detailed Description
The study is a multicentre, randomized, double-blind, placebo-controlled, parallel-group study in healthy children aged 5-8 years. The objective is to investigate the effect of a symbiotic lozenge on caries increment in primary molar teeth, primary canines and erupted occlusal surfaces at the first permanent molar teeth.The study will take place in Helsingør and Fredensborg municipality.
The study consists of a baseline visit prior to a 12 months intervention period, followed by a visit after completion. During the intervention period, two to four months after the baseline visit, a saliva sample will be collected.
All guardians to the subjects are encouraged to 1) brush their children's teeth twice daily with the fluoride toothpaste provided, 2) avoid the food provided in appendix D and 3) to continue the subject's dental appointments at local Public Dental Health Service (PDHS). No further specific oral hygiene or dietary instructions/restrictions are provided.
Assuming a dropout rate of 12.5%, 175 children will be included in each treatment group.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Dental Caries
7. Study Design
Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
343 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Active
Arm Type
Experimental
Arm Description
A lozenge containing 2 billion CFU in total of the two strains Lactobacillus paracasei subsp. paracasei and Lactobacillus rhamnosus and arginine 2% to be taken once daily
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
An identical lozenge except for the absence of probiotics and arginine to be taken once daily.
Intervention Type
Dietary Supplement
Intervention Name(s)
2 billion CFU in total of the two strains Lactobacillus paracasei subsp. paracasei and Lactobacillus rhamnosus and arginine.
Intervention Description
One lozenge once daily for 12 months
Intervention Type
Dietary Supplement
Intervention Name(s)
Placebo
Intervention Description
Placebo once daily for 12 months
Primary Outcome Measure Information:
Title
Increase in caries incidence
Description
Caries increment in primary molar teeth, primary canines and erupted occlusal surfaces at the first permanent molar teeth in children aged 5-8 years, using a modified dmf-s scale, including the occlusal surfaces of the first permanent teeth where d is defined by ICDAS scale and assessed both clinically and by dental x-ray.
Time Frame
12 months
10. Eligibility
Sex
All
Minimum Age & Unit of Time
5 Years
Maximum Age & Unit of Time
8 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
Healthy children with absence of severe chronic disease
Age 5-8 years, both inclusive, at inclusion
Ability to cooperate at dental examination
Ability to cooperate to a daily intake of a lozenge
Parents/legal guarding provided voluntary written informed consent
Exclusion Criteria:
Children with severe medical conditions
Mentally or physically disabled children
Children of parents with language barriers and not able to give written informed consent
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Azam Bakhshandeh, PhD
Organizational Affiliation
University of Copenhagen
Official's Role
Principal Investigator
Facility Information:
Facility Name
University of Copenhagen
City
Copenhagen
Country
Denmark
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
Effect of 12 Months Supplementation With a Symbiotic Lozenge on Caries Increment in Healthy Children
We'll reach out to this number within 24 hrs